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Varicella-zoster virus (VZV), the cause of chickenpox and zoster, was the first human herpesvirus
to be sequenced fully and the first for which vaccines have been licensed and widely used. Three
groups have published genotyping schemes based on single nucleotide polymorphisms (SNPs)
and, between them, have identified five distinct phylogenetic clades, with an additional two
putative clades. Sequencing of over 23 whole VZV genomes from around the world further refined
the phylogenetic distinctions between SNP genotypes. Widespread surveillance in countries in
which the varicella vaccine is now in use and the difficulties posed by three unique genotyping
approaches prompted an international meeting, at which a common nomenclature based on
phylogenetic clades was agreed upon. In this paper, we review the original genotyping schemes
and discuss the basis for a novel common nomenclature for VZV strains. We propose a minimum
set of SNPs that we recommend should be used to genotype these viruses. Finally, we suggest
criteria by which novel clades can be recognized.
Introduction
Varicella-zoster virus (VZV; Human herpesvirus 3)i sa
member of the genus Varicellovirus, subfamily Alpha-
herpesvirinae. VZV exclusively infects humans, causing two
diseases: chickenpox (varicella) following primary infection
and shingles (herpes zoster), which results from reactiva-
tion of latently persistent virus (Hope-Simpson, 1965).
VZV is related closely to other members of the genus
Varicellovirus, including suid herpesvirus 1 (which infects
pigs) and equine herpesviruses 1, 3, 4, 8 and 9, which infect
horses (McGeoch & Cook, 1994). The most closely related
human herpesviruses are herpes simplex virus 1 and 2.
Varicella, although a relatively benign childhood infection
in temperate countries, is nonetheless a cause of medically
and economically important morbidity and mortality
(Meyer et al., 2000; Preblud, 1986). In most countries,
between 2 and 4% of children are hospitalized for
complications of chickenpox, including secondary bacterial
infection, pneumonia and encephalitis (Sengupta et al.,
2008). Mortality in children is around 0–0.05 deaths per
100000 cases of chickenpox, primarily among children
who were previously healthy (Sengupta et al., 2008). Adult
infection, which is more common in tropical countries,
results in a 6-fold increase in hospitalizations and up to a
20-fold increase in deaths (Marin et al., 2008; Rawson
et al., 2001). Herpes zoster is a major cause of morbidity in
the elderly from persistent neuropathic pain (Dworkin
et al., 2007) and mortality in the immunocompromised,
particularly from dissemination of the acute rash. The
medical and economic burden of VZV disease has led to
the introduction of childhood vaccination programmes
against varicella in Japan, North America, parts of Europe,
other Asian countries and the Antipodes (Bonanni et al.,
Journal of General Virology (2010), 91, 821–828 DOI 10.1099/vir.0.017814-0
017814 Printed in Great Britain 8212009). More recently, a vaccine to prevent herpes zoster has
been licensed and is being administered to older people in
the USA (Oxman et al., 2005).
The VZV genome was one of the first human herpesvirus
genomes to be sequenced fully; this was done at the MRC
Virology Unit, Glasgow, UK (Davison & Scott, 1986). The
Dumas strain, which was originally isolated from a patient
with varicella in Holland, is approximately 125 kb in
length. Seventy-two open reading frames (ORFs) num-
bered 0–71 have been identified, of which 69 are unique
and three are duplicated (Fig. 1). Like other herpesviruses,
VZV has unique long and short regions and two inverted-
repeat regions, TR and IR, within which lie the duplicated
genes (Fig. 1). VZV genomes differ in size by up to
500 bases and the differences are due to variation in the
length of five tandem-repeat regions, R1–R5, and the viral
origin of replication OriS (Tyler et al., 2007). R1, R2 and
R3 lie with ORFs 11, 14 and 22, respectively, and are
included in the coding regions of those genes (Davison &
Scott, 1986). R4, R5 and the origin of replication OriS lie in
non-coding regions. R4 and OriS are duplicated, occurring
between ORFs 62 and 63 and ORFs 70 and 71. In recent
years, 23 full-length sequences of 18 VZV genomes
(Table 1) have been published, making the VZV genome
themost-studiedof thehumanherpesvirus genomestodate.
The second virus to be sequenced fully was the parental
vaccine strain pOka, as well as three preparations of the
vaccine strain vOKa (Gomi et al., 2002). Two groups, one at
the CDC and the other a collaboration between scientists at
the University of Iowa and the Canadian National Public
Health Laboratory, have published analyses of two and 11
novel genomes, respectively (Table 1) (Grose et al., 2004;
Norberg et al., 2006; Peters et al., 2006).
If the variable regions are excluded, there are between 30
and 200 single nucleotide polymorphism (SNP) differences
between any two genomes, i.e. between 1 in 4000 and 1 in
600 substitutions (Tyler et al., 2007). Approximately 30%
of these result in amino acid changes, and substitutions are
not distributed evenly. If mutations are standardized per
100 bases, ORFs 1 and 62 are the most variable, whereas
ORFs 3, 25 and 49 had no substitutions in 11 genomes
(Tyler et al., 2007). Considering the genome in its double-
stranded, linear form, the most variation occurs in ORFs
sited at either end of the genome, i.e. ORFs 1–3 and 57–68,
as well as in ORFs 35–37 (Tyler et al., 2007). The numbers
of substitutions observed in the unique short region appear
to be higher than in the unique long region, suggesting a
different evolutionary rate (McGeoch, 2009).
Although some VZV genotyping by restriction fragment
length polymorphism (RFLP) analysis of the variable
region was carried out in the 1980s and 1990s, it was the
development of SNP-typing tools that led to a better
understanding of VZV molecular epidemiology and
evolution. From 2000 onwards, SNP-based methodologies
for genotyping were published by two USA-based and one
UK-based groups (Barrett-Muir et al., 2001; Faga et al.,
2001; Loparev et al., 2004; Muir et al., 2002). SNPs are sites
that contain single base-pair variations (Collins, 1997).
These sites are generally considered biallelic, due to the
limited number of transversions that have been found
(Brookes, 1999; Kruglyak, 1997). Each allele must occur in
.1% of the population to be considered an SNP
(Kruglyak, 1997; Wang et al., 1998). Individuals who share
many of the same SNPs are likely to have arisen from a
common ancestor and can therefore be grouped by
inheritance (Collins, 1997; Faga et al., 2001).
The three SNP-based genotyping methodologies differ in
their approaches. The scattered SNP method, developed
by the Breuer group in the UK, used heteroduplex-
mobility assays to identify 92 polymorphisms in 37 ORFs
spread evenly across the VZV genome (Barrett-Muir et al.,
2001; Muir et al., 2002). This research group identified
three distinct phylogenetic genotypes circulating in the
UK and a fourth in Japan. The Iowa group, led by Grose,
sequenced five glycoprotein genes and the ORF encoding
the major immediate-early transactivating protein, IE62.
Sixty-one polymorphisms, 21 in the glycoproteins and
40 in ORF 62, were identified (Faga et al., 2001). Phylo-
Fig. 1. Schematic representation of the VZV genome showing the ORFs, numbered from left to right. . represent the positions
of single-nucleotide polymorphisms (SNPs) that have been identified as useful for strain genotyping. Black-filled shapes
represent ORFs that are transcribed late in the VZV replication cycle. IR, Inverted repeat; TR, terminal repeat; UL, unique long
region; US, unique short region.
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et al., 2006). The third group, led by Schmid at the CDC,
located a 447 bp fragment in ORF 22 upstream of the C-
terminal coding region that was sufficiently polymorphic
to allow identification of four viral clades (Table 2)
(Loparev et al., 2004). Between them, the three groups
identified five distinct clades, although no one group
identified all five. The different nomenclatures used by
each group are shown in Table 2 and the SNPs used for
genotyping in Table 3.
Whole-genome sequencing
The phylogeny of VZV was further informed by whole-
genome sequencing carried out by US–Swedish and US–
Canadian collaborations (Norberg et al., 2006; Peters et al.,
2006). Until this time, seven full-length sequences were
available: the Dumas strain, the Biken, Merck and GSK
strains of the Oka vaccine strain, parental Oka, and MSP
and BC, in which the identical amino acid substitution
D150N had been reported in glycoprotein E (Davison &
Scott, 1986; Gomi et al., 2002; Grose et al., 2004). The US
(Iowa)–Canadian collaboration reported an additional 11
strains, whilst the US–Swedish collaboration reported
partial sequence from an additional two strains. In the
latter, repeat and tandem-repeat regions, including the R1–
R5 and OriS regions, were excluded (Norberg et al., 2006).
In the first study, all 11 additional strains sequenced were
collected from North America, whilst in the US–Swedish
study, one strain originated from Morocco and the second
from the USA (Norberg et al., 2006; Peters et al., 2006). At
the same time, the Iowa–Canadian group carried out the
definitive investigation of virus stability. Repeated passage
of a virus in cell culture followed by whole-genome
sequencing showed that, excluding unstable repeat regions,
one substitution (8610
26 substitutions per base) occurred
following 20 passages and 28 substitutions (2.2610
24 per
base) after 72 passages. This suggests that, above 20
passages, the virus becomes unrepresentative of the original
(Tyler et al., 2007). Table 1 shows the common clade
nomenclature agreed upon at a meeting held in 2008,
alongside each of the others; this will be used from this
point forward. The power of full-length sequence to
Table 1. VZV whole genomes, GenBank accession numbers and references
GenBank accession no. VZV strain Clade Reference
X04370 Dumas 1 Davison & Scott (1986)
EU154348 SVETA Loparev et al. (2009)
DQ674250 NH29_3 V. N. Loparev, direct submission to GenBank (5 June 2006)*
DQ479963 32 passage 72 1 Peters et al. (2006)
DQ479962 32 passage 22 1 Peters et al. (2006)
DQ479961 32 passage 5 1 Peters et al. (2006)
DQ479960 8 4 Peters et al. (2006)
DQ479959 49 1 Peters et al. (2006)
DQ479958 36 1 Peters et al. (2006)
DQ479957 03-500 3 Peters et al. (2006)
DQ479956 22 3 Peters et al. (2006)
DQ479955 11 3 Peters et al. (2006)
DQ479954 Kel 1 Peters et al. (2006)
DQ479953 SD 1 Peters et al. (2006)
DQ457052 CA123 5 Norberg et al. (2006)
DQ452050 DR 4 Norberg et al. (2006)
AJ871403 HJ0 3 Norberg et al. (2006)
DQ008355 VariVax 2 Tillieux et al. (2008)
DQ008354 VarilRix 2 Tillieux et al. (2008)
AY548170 MSP 1 Grose et al. (2004)
AY548171 BC 1 Grose et al. (2004)
AB097933 Oka, substrain pOka 2 Gomi et al. (2002)
AB097932 Oka, substrain vOka 2 Gomi et al. (2002)
*NCID, CDC, 1600 Clifton Rd, Atlanta, GA 30333, USA.
Table 2. Genotyping nomenclatures in current use
Nomenclature Based on: Prototypic strain
Dumas pOka 11 8, DR CA123
Iowa–Canada Glycoprotein A B D C
UK Scattered SNP C J B A2/J2 A
CDC ORF 22 E1 J E2 M2 M1
New Whole genome 1 2 3 4 5
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esis was exemplified by work on the MSP and BC strains of
VZV. In 2000, the Grose laboratory described the MSP
virus, in which a mutation in a glycoprotein E (gE) B-cell
epitope abrogated binding of an anti-gE antibody (Santos
et al., 2000). Two years later, the same gE amino acid
mutation was described by the Tipples group in a Canadian
VZV community isolate, strain BC (Tipples et al., 2002). As
the VZV genome is extremely stable, it was initially unclear
whether the mutations in BC and MSP had arisen
independently. The Iowa–Canadian collaboration hypothe-
sized that MSP and BC might indeed represent a distinct
subclade that was now spreading independently in North
America. Sequencing of full-length genomes established
that the viruses, although both belonging to clade 1, were
not related more closely to each other than they were to
other viruses within the same clade (Grose et al., 2004).
Thus, the substitution in gE was a homoplasty, i.e. an
identical mutation that had arisen in an evolutionarily
independent manner in two unrelated viruses, most
probably to escape neutralizing antibody. Subsequently,
in an analysis of 634 VZV isolates collected at the
Karolinska University Hospital, Sweden, two additional
similar gE mutant viruses were discovered (Wirgart et al.,
2006).
Early on, opportunistic genotyping by many groups
identified differences in the global distribution of the five
clades (Loparev et al., 2004; Muir et al., 2002; Wagenaar et
al., 2003). Two clades (1 and 3) were found in European
countries and areas of the world predominantly settled by
Europeans, whilst clade 2 was identified as being
predominantly present in Japan and surrounding countries
(Loparev et al., 2004; Muir et al., 2002; Wagenaar et al.,
2003). Because the varicella vaccine was developed in
Japan, the majority of sequenced clade 2 strains originated
from Japan. The two remaining clades, 4 and 5, are most
prevalent in Asian and African countries (Loparev et al.,
2004, 2007b; Muir et al., 2002; Wagenaar et al., 2003). The
results obtained from genotyping of opportunistically
collected samples were confirmed by analysis of zoster
samples collected prospectively from European subjects
living in the UK, the oldest of whom was over 100 years of
age (Sengupta et al., 2007). Making the assumption that the
virus reactivating as zoster and the virus responsible for
primary infection were the same strain, it was confirmed
that the European clades 1 and 3 were present in 90% of
Caucasians living in the UK and that this prevalence had
not changed over the past 100 years. Reassuringly, this
validated the conclusions about geographical distribution
of strains and supported the value of opportunistic
genotyping. These findings have enabled a number of
groups to observe an increased circulation of clade 5
viruses in recent years (Hawrami et al., 1997; Quinlivan et
al., 2002; Sauerbrei & Wutzler, 2007).
Following the initial publications, the CDC group added
SNPs from ORFs 21 and 50 to those used originally in the
ORF 22 genotyping scheme (Table 2) (Loparev et al.,
2007b; Sergeev et al., 2006). Using these, they have
suggested that, in addition to the five existing phylogenetic
clades, there may be two additional stable clades, which
they designated M3 and M4 (Loparev et al., 2007b, 2009;
Sauerbrei et al., 2008; Sergeev et al., 2006) (Table 2; Fig. 2).
M4 is negative for a BglI site in ORF 54, which is a
characteristic feature of the ‘European origin’ clades 1 and
3 (Quinlivan & Breuer, 2006; Sengupta et al., 2007) and has
in fact been shown by the CDC group to resemble
European clades 1 and 3 (Loparev et al., 2009). It is
possible that they may be the same as the viruses described
as clade 1 and 3 ‘recombinants’ by the UK group (Muir et
al., 2002). However, extensive SNP typing has shown M4
to have unique SNPs that are not shared with any other
clade. The data suggest that, once full-length sequence has
been obtained, the status of M4 as an independent clade is
likely to be confirmed (Loparev et al., 2009). The status of
M3 is less certain. The virus is positive for the ORF54 BglI
site, in which respect it resembles the clade 2, 4 and 5
viruses that predominate in Japan, Asia and Africa,
respectively. M3 has been described only a few times and
Table 3. Minimum complement of SNPs required to identify a
putative clade
SNPs are given as the nucleotide position according to GenBank
accession no. X04370 (Dumas). ND, Not determined.
ORF SNP Clade
12345 V I V I I
1 508 C C C C C T ND
1 6 8 5 GAGAGG ND
1 790 T C T C C T ND
6 5827 C C A C C C ND
6 6850 G G G A A G ND
12 17834 C T C T C T ND
12 18082 C T C C C C ND
16 23294 A G G A G G ND
17 24533 A A A A C A ND
17 24578 A G G A G G ND
21 33725 T C C C C C ND
22 37902 A G A A A A G
22 38019 G G G A G G G
22 38055 T C T C T T T
22 38081 A C A C C C C
22 38177 G A G A G A G
22 39394 G A A G A A ND
35 64703 G G G A A G ND
37 68101 T T C T T T ND
37 68172 G A A A A A ND
37 68254 C C T C C T ND
50 87841 C T T T T T ND
54 95241 T C T C C T ND
55 98437 T C T C T C ND
56 98825 T T T C C C ND
60 101464 C C C C A C ND
66 113243 A A C C A C ND
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as an independent clade (Loparev et al., 2007a; Sergeev et
al., 2006).
The 2008 VZV nomenclature
To resolve the confusion associated with three different
genotyping classifications, a meeting (see attendance list in
Acknowledgements) to discuss a common nomenclature
was held in London, UK, in 2008. Four principles were
agreed upon: that the new nomenclature should be distinct
from the three established nomenclatures, that it should
reflect the phylogenetic structure of VZV strains, that it
should reflect the order in which full-genome sequences
were published or deposited in the databases, and that it
should describe the provenance of the strain. To that end,
the proposed nomenclature for VZV and the prototypic
viruses for each clade are shown in Table 2 and Figs 2 and
3. A summary of the proposed nomenclature overall is
shown in Fig. 2. We have used the word ‘clade’ to designate
an evolutionarily distinct subspecies of VZV. The intention
is that each clade should have at least two whole genomes.
Clades 2 and 5 have only one genome and further work to
generate a second prototype for each clade is ongoing.
Several principles for naming strains have been agreed and
are listed below.
1. Strains of VZV will now be identified by the
disease (varicella, zoster or latent).
2. Novel viruses will be designated a member of an
existing clade, based on phylogenetic clustering or
SNP profile as outlined in Table 3.
3. Strains will be identified as cultured isolates (i) or
sequence (s).
4. The geographical and temporal origin of the virus
will be identified.
5. Putatively novel clades will be identified by Roman
numerals until confirmed as a clade.
Some of the laboratories that can provide support for
genome sequencing are listed in Table 4.
Future studies
Vaccination programmes to prevent varicella in children
are now established in many resource-rich countries,
and surveillance of viral genotypes has been set up by
some to support these efforts (Table 4). Reference
genotyping of varicella is provided by several countries
and the establishment of a common nomenclature will
facilitate interchange of information. In particular, the
success of the vaccine programmes in preventing wild-
type varicella and of genotyping the viruses causing
outbreaks has been, and will continue to be, central to
ongoing implementation and improvement. Most
Fig. 2. Proposed new VZV nomenclature
system, adopted 25 July 2008, Whitechapel,
London, UK. Summary: major circulating clus-
ters are designated as clades; there are no
geographical implications in the naming
system; established clades are designated by
Arabic numerals; provisional clades are desig-
nated by Roman numerals. Reference strains
for each clade are indicated in bold; additional
reference strains are required for clades 2, 5,
VI and VII.
Fig. 3. Phylogenetic tree showing five major VZV clades (adapted
from Loparev, 2007b). Previous genotyping schemes are shown in
the order Breuer/Schmid/Grose.
VZV nomenclature
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ant viruses provides a challenge for which the unified
nomenclature and common genotyping will be import-
ant, not only for surveillance but also for pathogenesis
(D. S. Schmid, unpublished data). Of the three such
recombinants analysed so far, two are vaccine-clade 1
and one is vaccine-clade 3. This discovery was not
totally unexpected, as recombination between two
different live vaccine viruses has been documented
previously with pseudorabies virus, an alphaherpesvirus
that infects pigs (Dangler et al., 1993). A common
nomenclature will also allow better understanding of
VZV genome biology, including the emergence of new
strains following biological and immune selection across
functionally important regions. Finally, there is still
work to be done on defining relatedness between strains
of the same clade for investigation of outbreaks. The
stability of the VZV genome and low numbers of
substitutions between strains, particularly within the
same clade, preclude the use of SNPs for transmission
studies. However, signature sequences that are unique or
uncommon may be useful for establishing chains of
transmission, as was the case in an outbreak of varicella
in a residential care home (Lopez et al., 2008). An
alternative approach is to make use of repeat regions
within the VZV genome, which evolve at a faster rate.
Two such regions that have been used to investigate
hospital transmissions are R1 in ORF 11 (Molyneaux
et al., 2006; Tang et al., 2005) and OriS (J. Breuer,
unpublished data). However, the precise parameters that
will inform their use for investigation of outbreaks
remain to be established. Ultimately, genome sequen-
cing may prove to be the most useful tool for inves-
tigation of VZV transmission events.
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Country Institution Contact SNP genotyping Whole-genome
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SNPs in ORFs 38, 54 and 62
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Australia Institute of Clinical
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